Thirteen states maintain sweeping abortion bans at all pregnancy stages
Thirteen states enforce complete abortion bans at all pregnancy stages, creating the nation's most restrictive landscape.
Event / Politics
Federal court proceedings over mifepristone mail access and FDA approval. Multiple states pursuing restrictive policies while others protect telehealth providers. Supreme Court and various courts addressing medication abortion availability.
2026-08-19 to 2026-11-16 · UTC publication dates
Coverage begins 8 Apr, 02:07 UTC
Follow the documented timeline or explore the related reporting.
Research found that by the end of 2024, one-fourth of all abortions in the United States were accessed through telehealth—representing a fivefold increase over two years. In 2025, women in states with abortion bans were more likely to obtain abortions by obtaining pills through telehealth than by traveling to other states.
Judge David Joseph directed the FDA to provide an update on its mifepristone investigation within six months. He stated that if the agency fails to complete its review and make necessary revisions to its rules within a reasonable timeframe, his analysis and the weight accorded to various factors would inevitably change, signaling he may reconsider his position.
Louisiana Attorney General Liz Murrill announced she would appeal the federal court's decision to an appeals court, seeking to overturn FDA rules permitting mifepristone mail delivery. Murrill argued that the judge's opinion acknowledged Louisiana suffers irreparable harm daily while these rules remain in effect.
A Hawaii federal judge ruled that the FDA violated the law by imposing restrictions on mifepristone, which is used for both abortion and miscarriage management.
U.S. District Judge David Joseph in Lafayette, Louisiana ruled against Louisiana Attorney General Liz Murrill's request to pause FDA rules allowing mifepristone to be dispensed by mail. The judge granted the government's request to put the case on hold temporarily, though he indicated the pause would not be indefinite and warned he could side with Louisiana later. The judge said plaintiffs are 'likely to succeed on the merits' but will await completion of an FDA study on the drug.
The Trump administration approved an additional generic version of mifepristone, a decision that outraged anti-abortion advocacy groups. Mifepristone is used both for abortion and for miscarriage management.
Louisiana is one of 13 states that currently enforce complete abortion bans prohibiting abortion at all stages of pregnancy. Similar court challenges to mifepristone mail rules are being pursued by Republican state officials in other districts.
Eight states have enacted laws designed to protect healthcare providers who prescribe abortion pills via telehealth and have them mailed into states with abortion bans. These laws aim to shield providers from legal liability in conservative states.
Louisiana Attorney General Liz Murrill is pursuing criminal cases against two doctors—one in California and one in New York—accused of sending mifepristone pills to patients in Louisiana. California and New York have declined to extradite the doctors to face charges in Louisiana.
In 2024, the U.S. Supreme Court refused to block filling prescriptions for mifepristone by mail. That case differed from the current Louisiana lawsuit because it was brought by anti-abortion doctors whom the Court determined lacked legal standing to challenge the FDA rules.
Thirteen states enforce complete abortion bans at all pregnancy stages, creating the nation's most restrictive landscape.
Mifepristone access expanded through telehealth adoption, state legal protections, and new generic approvals.
Louisiana appeals mifepristone ruling and pursues cross-state provision prosecutions.
Courts blocked restrictions on mifepristone mail access across federal and state levels.